Vincristine/irinotecan/temsirolimus upfront window treatment of high-risk hepatoblastoma: A report from the Children's Oncology Group AHEP0731 Study Committee.

Patrick A Thompson,Marcio H Malogolowkin,Wayne L Furman,Jin Piao,Mark D Krailo,Nadia Chung, Lindsay Brock,Alexander J Towbin,Elizabeth B McCarville,Milton J Finegold,Sarangarajan Ranganathan,Stephen P Dunn,Max R Langham,Eugene D McGahren,Gregory M Tiao,Christopher B Weldon,Allison F O'Neill,Carlos Rodriguez-Galindo,Rebecka L Meyers,Howard M Katzenstein

Pediatric blood & cancer（2023）

引用 2|浏览40

暂无评分

摘要

VIT did not achieve the study efficacy endpoint. Temsirolimus does not improve the response rate seen in patients treated with vincristine and irinotecan (VI) alone as part of the initial treatment regimen explored in this study. Additionally, AFP response may be a more sensitive predictor of disease response than RECIST in HB.

查看译文

关键词

chemotherapy,hepatoblastoma,high-risk,irinotecan,metastatic

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要